Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the ...
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –
United States Hynes Convention Center Andrew Robbins Christi Waarich Cogent Biosciences Inc International Conference On Molecular
Source: eagletribune.com